Clinical Trial Search

Primary: Change From Baseline in Eczema Area and Severity Index (EASI) — -8.65; -6.95 Score on a scale

Primary: Change From Baseline in Mean Number of Nocturnal Voids — -1.12; -1.30; -1.42; -1.47 nocturnal voids

Primary: Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] — -1.579; -1.110 units on a scale

Primary: Number (%) of Subjects With Drug Related Adverse Events — 0.0; 33.3; 16.7; 0.0 Percentage of Participants

Primary: Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value…

Primary: Skill in Intubating Neonatal Manikin — 23.4; 39.9 seconds — p=0.039

Primary: Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab — 1600 mg

Primary: Percentage of Study Participants Achieving Menactra Response for Meningococcal Serogroups A, C, Y, and W-135 Following the Second Menactra Vaccination — 96.24; 96.35…

Primary: Percentage of Subjects Achieving a 24 Hour Average Total Serum Testosterone Concentration (Cavg,0-24h) in the Range of 300 to 1050 ng/dL After 15 Days of Treatment With…

Primary: Modified Rankin Score

Primary: Change in Serum Potassium From Part A Baseline to Part A Week 4 — -1.01 mEq/L — p=<0.001

Primary: Number of Subjects That Report at Least One Treatment-emergent Adverse Event During the Study (Approximately 13 Weeks) — 14; 19; 9 participants

Primary: Change From Baseline in Serum Potassium to the End of the 28-day Treatment Period. — -0.21; 0.23 mEq/L — p=< 0.001

Primary: Diagnostic Accuracy. — 88; 62 Percentage of participants

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as a Measure of Safety — 84.5; 2.8 percentage of participants